Two-year partnership with plans to extend
Belgian biotechnology company Galapagos is to work with researchers at the Edinburgh Cancer Discovery Unit (ECDU) to develop new treatments for cancer.
Edinburgh BioQuarter negotiated the partnership between the University of Edinburgh and Galapagos, which will initially run for two years, with plans to develop a longer-term collaboration and focus on developing innovative medicines.
‘Working with our team, Galapagos will be able to access a wide range of advanced cancer models and technical capabilities established within the Edinburgh Cancer Discovery Unit, as well as the team’s outstanding knowledge and expertise,’ said Dr Neil Carragher, principal investigator at the Edinburgh Cancer Research Centre.
Edinburgh BioQuarter is a joint venture between Scottish Enterprise, the NHS, the University of Edinburgh and Alexandria Real Estate Equities.